Key Points {#FPar1}
==========

Patients compare psychedelic treatments favorably with conventional treatments, emphasizing the importance of non-pharmacological factors such as trust, safety, interpersonal rapport, attention, the role of music, and the length of treatment sessions.Pharmacologically distinct psychedelics exhibit overlapping therapeutic processes for different mental disorders, including insights, altered self-perception, increased feelings of connectedness, transcendental experiences, and an expanded emotional spectrum.Patients frequently report on clinical effects beyond their own psychiatric diagnosis, which may be indicative of the cross-diagnostic action of psychedelic drugs, by setting in motion therapeutic processes that address core elements of a shared psychopathology across mental disorders.

Introduction {#Sec1}
============

The recent resurgence of clinical interest in the use of psychedelics for the treatment of mental disorders is evidenced by a sharp increase in studies and publications. After a decades-long research hiatus, psychedelics have been investigated as potentially effective treatments for several mental disorders, including substance use disorders (SUDs) \[[@CR1]--[@CR4]\]; post-traumatic stress disorder (PTSD) \[[@CR5]--[@CR10]\]; anxiety, and depression secondary to a life-threatening illness \[[@CR11]--[@CR14]\]; social anxiety in autistic adults \[[@CR15]\]; obsessive--compulsive disorder (OCD) \[[@CR16]\]; depression \[[@CR17]--[@CR22]\]; and suicidal ideation \[[@CR23]\]. Psychedelic drugs include a range of pharmacologically diverse substances comprising 'classic' serotonergic psychedelics (psilocybin, lysergic acid diethylamide \[LSD\], and the dimethyltryptamine \[DMT\]-containing ayahuasca), entactogens (e.g. the serotonin-releasing drug 3,4-methyenedioxymethamphetamine \[MDMA\]), the atypical psychedelic ibogaine and dissociative anesthetics such as the *N*-methyl-[d]{.smallcaps}-aspartate (NMDA) antagonist ketamine. All these substances can induce alterations of conscious states, as well as a wide range of psychological, cognitive, emotional, and biological effects that may be relevant for their therapeutic action, when administered within a (psycho)therapeutic context \[[@CR24]--[@CR28]\].

The safety, clinical benefits and therapeutic outcomes of these interventions are thought to be fundamentally reliant on a supportive environment \[[@CR29], [@CR30]\], with 'set' and 'setting' playing a crucial role \[[@CR31], [@CR32]\]. 'Set' includes internal, psychological variables such as personality, expectations, suggestibility, preparation, intentions, and mood and psychopathology, while 'setting' is understood to mean the external environment in which the experiences take place, including the physical, interpersonal, and broader social and cultural contexts \[[@CR33]--[@CR36]\]. Therapeutic use of psychedelics takes place in different settings. Modern clinical research with psilocybin, LSD and MDMA is typically conducted in the context of so-called 'psychedelic-assisted psychotherapy', which is a complex and variable modality that involves the administration of a psychedelic drug to facilitate or catalyze a therapeutic process \[[@CR37]\]. Typically, this takes place in the presence of one or two therapists, and often involves the use of music to facilitate an introspective experience \[[@CR33], [@CR38], [@CR39]\]. The Amazonian brew ayahuasca is typically consumed in traditional shamanic, religious, and hybrid ceremonial settings \[[@CR40]\], whereas ibogaine is administered in both unlicensed 'medical subcultures' \[[@CR41]\] and in private clinics such as in Mexico and New Zealand \[[@CR42], [@CR43]\]. On the other hand, the atypical psychedelic ketamine is normally administered as a standalone pharmacotherapy in a clinical setting \[[@CR44]\].

It has been suggested that the influence of these extrapharmacological variables contributes significantly to the substances' pharmacological qualities \[[@CR33], [@CR35]\], as evidenced by the high variability of individual experiences. Studies have emphasized the importance of the subjective experience \[[@CR29]\], and several potential psychological mediators for therapeutic outcomes have been postulated in treatments with psychedelics, e.g. (sustained) changes in openness \[[@CR45]--[@CR47]\], prosocial feelings \[[@CR45], [@CR48]\], increases in suggestibility \[[@CR49]\], meaning making \[[@CR50]\], self-efficacy \[[@CR51]\], and connectedness \[[@CR52], [@CR53]\]. Furthermore, psychological flexibility \[[@CR54]\], emotional breakthroughs \[[@CR55]\], psychological insights \[[@CR51]\], the loss of sense of self ('ego dissolution') sometimes resulting from mystical or peak experiences \[[@CR29], [@CR56]--[@CR58]\], and experiences of awe \[[@CR59]\] have been mentioned.

A close examination of patients' experiential accounts could increase our understanding by providing more detailed insight into these and other underlying (psychological) mechanisms. Given the highly personalized nature of psychedelic-induced patient experiences, quantitative measurements might not capture the full spectrum of phenomena experienced by patients. Qualitative inquiry is typically concerned with understanding the how, what, or why of a particular phenomenon and can generate a more holistic account of the issue being studied \[[@CR60], [@CR61]\]. This is especially relevant in this emerging field of research. This makes qualitative research well-suited to explore the rich subjectivity of respondents' inner experiences, their attributions of meaning, the treatment context, and help inform a more detailed understanding of these complex interventions and underlying psychological mechanisms. These may in turn better tailor future research as well as inform and improve therapeutic effectiveness. Qualitative inquiry can also complement quantitative research by generating, rather than validating, hypotheses, which can be tested using quantitative instruments.

While some qualitative research efforts have been directed at exploring the role of the subjective psychedelic experience in the treatment of mental disorders, to date no systematic review exists. This article aims to address this lacuna by presenting an overview of the available qualitative research. Identifying salient themes across studies, this review presents both common and diverging elements in patients' accounts of their experiences, how they relate to their disorders, therapeutic processes, and personally and clinically significant outcomes. A systematic literature review was conducted of qualitative studies that address what patients report after taking a psychedelic substance in the context of treatment of a mental disorder.

Methods {#Sec2}
=======

We systematically identified and reviewed the selected studies using the Preferred Reporting Items for Systematic Reviews and Meta-Analyses (PRISMA) guidelines, which offer an extensive checklist and flowchart to improve the quality of systematic reviews \[[@CR62]\].

Selection Criteria {#Sec3}
------------------

For this systematic review we selected papers that described patient experiences after taking a psychedelic for the purpose of treating a mental disorder. The eligibility criteria for inclusion in the review were qualitative research design; peer-reviewed studies in English; based on verbalized patient utterances; and a level of abstraction or analysis of the results. Eligibility criteria for inclusion were based on a modified PICo framework for qualitative reviews \[[@CR63]\]. We employed a broad definition of psychedelics (see Table [1](#Tab1){ref-type="table"}).Table 1PICo frameworkPopulationPatients with a mental disorder seeking treatmentPhenomenon of InterestExperiences elicited/induced by the deliberate administration of psychedelic substances, including classic psychedelics such as psilocybin, LSD, mescaline, and ayahuasca, as well as atypical psychedelics such as ibogaine, salvinorin A, MDMA and ketamine, but excluding cannabisContextTherapeutic setting, context that facilitates therapeutic experiences*LSD* lysergic acid diethylamide, *MDMA* 3,4-methylenedioxymethamphetamine

Search Strategy and Study Selection {#Sec4}
-----------------------------------

We conducted a systematic search between 5 and 12 March 2019. The PubMed, MEDline, PsycINFO, and EMBASE databases were searched extensively and systematically without time limitations, using combinations of both index terms (Medical Subject Headings \[MeSH\] in PubMed, Emtree in Embase, and Thesaurus in PsycINFO) and free-text terms in two categories. The first category included a broad range of psychedelic substances, including the atypical psychedelics ketamine, ibogaine, and MDMA. The second category involved the type of data that were gathered (e.g. "patient experience\*", "phenomenology", "patient perspective\*", "participant experience\*", "subjective experience\*") and the qualitative methodology (e.g. "qualitative research", "semi-structured interview\*", "focus group\*", "qualitative methods", "thematic analysis", "grounded theory", "interpretative phenomenological analysis"). All databases were searched using "OR-relations" within these categories, and "AND-relations" between categories. A detailed account of the searches can be obtained from the first author upon request. The systematic search was complemented by hand searching, including reference lists of identified articles as well as relevant, non-indexed journals. The selection process was conducted according to the eligibility criteria as presented in the PRISMA flow diagram in Fig. [1](#Fig1){ref-type="fig"}.Fig. 1Systematic search flowchart

Data Analysis and Synthesis {#Sec5}
---------------------------

Qualitative research seeks to develop a contextual understanding of behavior in the natural environment it observes. This does not mean that generalizability is impossible, but rather that theoretical generalization, i.e. transference, must be separated from statistical significance \[[@CR64]\]. Whereas systematic review methods are well developed for randomized controlled trials (RCTs), no single preferred methodology exists to guide analysis and synthesis of qualitative data \[[@CR65], [@CR66]\] or to guide critical appraisal of study methodology and validity \[[@CR67]--[@CR69]\]. For this review, we employed thematic synthesis \[[@CR70]\], based on thematic analysis \[[@CR71]\], as this approach is particularly useful for bringing together heterogeneous studies \[[@CR72]\]. Since we did not want to exclude potentially relevant articles a priori, we conducted a post-synthesis sensitivity analysis \[[@CR68]\] using the Critical Appraisal Skills Programme (CASP) checklist, also in order to assess the methodological rigor of the studies \[[@CR73]\].

Thematic synthesis took place in three stages. First, all included articles were read and re-read carefully several times by the first author, allowing him to become thoroughly familiar with the content of the material. We were primarily interested in patient experiences, therefore, as our primary data, we took the results sections of all articles, including the categories and subthemes identified by the articles' authors. The first author then interpreted the data, and assigned primary codes. Parallel, he noted down comments, observations and reflections. Second, these codes were examined for similarities and differences, and were rewritten with a higher level of (psychological) abstraction into themes. Finally, these themes were subsequently reanalyzed and grouped together by all authors, based on conceptual similarities; these clusters comprised major themes and were given a descriptive label. We paid specific attention to potential similarities and differences by substance. All authors discussed additional analyses, and, where needed, categories were refined.

Results {#Sec6}
=======

Study Selection {#Sec7}
---------------

The initial literature search identified a total of 1660 results (PubMed, *n *=1025; PsycINFO, *n *=232; and EMBASE, *n *=403, and additional hand searches yielded five extra records. After removal of duplicates, the remaining 1472 publications were screened. Screening titles and reading abstracts resulted in the exclusion of 1375 titles. Ninety-seven full-text articles were obtained and read. Relevant information was extracted and assigned an additional code of yes/no/maybe, according to the inclusion criteria. Seventy-nine additional articles were excluded for not meeting the criteria (see Fig. [1](#Fig1){ref-type="fig"} for a further breakdown of the reasons). Three articles were excluded at a late stage: one study on the clinical use of MDMA \[[@CR74]\] was ultimately excluded as it did not target a specific mental disorder and had unclear research methodology and study aims. Two recent psilocybin studies \[[@CR75], [@CR76]\] were also excluded as they presented a series of case studies, without additional analysis. Finally, 15 studies, with a total of 178 patients, were included in the systematic review.

Study Characteristics {#Sec8}
---------------------

All articles were published between 2014 and 2019. Where reported, respondents' ages ranged from 21 to 67 years, and the number of included subjects ranged from 4 \[[@CR77]\] to 22 \[[@CR78], [@CR79]\]. Studies were heterogeneous in terms of substances, population/mental disorders, contexts, and qualitative research methodologies. For an overview of all substances and disorders, please see Table [2](#Tab2){ref-type="table"}.Table 2Qualitative research categorized by mental disorder and psychedelic substanceAyahuascaIbogaineKetamineLSDMDMAPsilocybinEnd-of-life anxietyGasser et al. (2015) \[[@CR85]\]Swift et al. (2017) \[[@CR81]\]Belser et al. (2017) \[[@CR82]\]Depressive disordervan Schalkwyk et al. (2017) \[[@CR84]\]Watts et al. (2017) \[[@CR53]\]Eating disorderRenelli et al. (2018) \[[@CR88]\]Lafrance et al. (2017) \[[@CR87]\]Post-traumatic stress disorderBarone et al. (2019) \[[@CR80]\]Substance use disorder (specific drug used)Loizaga-Velder and Verres (2014) (mixed) \[[@CR90]\]Talin and Sanabria (2017) (not specified) \[[@CR89]\]Camlin et al. (2018) (opioids) \[[@CR86]\]Schenberg et al. (2017) (cocaine, others) \[[@CR78], [@CR79]\]Noorani et al. (2018)(tobacco) \[[@CR83]\]Nielson et al. (2018)(alcohol) \[[@CR77]\]*LSD* lysergic acid diethylamide, *MDMA* 3,4-methylenedioxymethamphetamine

All studies on psilocybin, LSD, ketamine, and MDMA took place in the context of clinical research in the US \[[@CR80]--[@CR84]\], Switzerland \[[@CR85]\] and the UK \[[@CR53]\]. Ibogaine treatments took place in treatment centers in Mexico \[[@CR86]\] and Brazil \[[@CR78], [@CR79]\], while ayahuasca was used in ceremonial \[[@CR87], [@CR88]\], religious \[[@CR89]\] or treatment contexts \[[@CR90]\].

Critical Appraisal of Study Quality {#Sec9}
-----------------------------------

The quality of the included studies varied. Based on the CASP criteria \[[@CR73]\], one study could be considered as low to medium quality \[[@CR78]\] and two as medium quality \[[@CR86], [@CR89]\]. The majority of the studies were rated as medium/high \[[@CR79], [@CR80], [@CR85], [@CR90]\] to high quality \[[@CR77], [@CR81]--[@CR84], [@CR87], [@CR88], [@CR91]\]. Overall, we found the validity, ethical considerations, and value of the studies to be of high quality. Critical reflections on the researchers' roles and relationship with participants varied widely, but this was not reflected in the overall quality assessment. Across the board, the rigor of the data analysis varied most and had the most room for improvement. An overview of the quality assessment of all included papers is presented in Appendix A. In order to examine the extent to which quality variations may have influenced the thematic synthesis, we conducted a post hoc sensitivity analysis. Assessing the relative contribution of the included studies to the thematic synthesis and overall themes, we found that lower-quality studies and studies with divergent research aims contributed comparatively less to the synthesis. The specific study aims and objectives correlated most clearly with the thematic synthesis. For instance, studies that aimed to address patients' subjective experience of a substance's psychoactive effects \[[@CR79], [@CR84], [@CR86], [@CR88]\] contributed mostly to the phenomenology section. The studies that focused on patient experiences of the therapeutic process \[[@CR82], [@CR85], [@CR88]\], aimed to increase the understanding of these complex treatments \[[@CR81], [@CR82], [@CR85], [@CR90]\], or (also) aimed to characterize, describe, or determine potential therapeutic mechanisms, effects, and processes \[[@CR53], [@CR82], [@CR83], [@CR85], [@CR87], [@CR90]\] contributed most to the perspectives on the intervention, therapeutic processes and outcomes. While we found quality differences, no articles were excluded based on our quality assessment. A complete overview of study aims, qualitative methodology and other study characteristics can be found in Table [3](#Tab3){ref-type="table"}.Table 3Overview of study aims, substances, population, diagnosis, treatment context, data sources and qualitative methodologyStudyStudy aimsSubstance, dose, and frequencyPopulation: *n*, sex, age range (years)Diagnosis/symptomsTreatment contextData sourcesQualitative methodologyLoizaga-Velder and Verres (2014) \[[@CR90]\]To broaden knowledge of ayahuasca-assisted therapy for substance dependenciesTo describe possible psychotherapeutic mechanismsTo identify variables that may influence treatment outcomesTo identify possible risksTo explore the possibilities of integrating this approach into Western countriesAyahuascaDose and frequency not reported*n* = 14Sex not reportedAge range 24--52Substance dependenceDiverse treatment settings in South America providing ayahuasca-assisted therapy for addictionParticipation in ayahuasca ritual without formal treatmentField observationsParticipative observationProblem-centered interviewsTextual resources (e.g. patient files and statements)CAGasser et al. (2015) \[[@CR85]\]To evaluate the long-term effects on anxietyTo explore subjective experiences and lasting psychological changesTo explore subjective experiences and elements of the therapeutic processTo gain a more holistic understanding from a client-centered perspectiveLSD1 × 200 μg LSD*n* = 10 (4 females)Age range 39--64Anxiety associated with a life-threatening diseasePhase II, double-blind, active placebo-controlled, randomized clinical trial, conducted in a private psychiatric practice in SwitzerlandSemi-structured interviews, conducted 12 months after the last session, in the patient's home or over the phoneQCALafrance et al. (2017) \[[@CR87]\]To explore possible psychological and physical effectsTo explore the perceived impact of the preparatory diet and experience of the ayahuasca purgeAyahuasca1--30 × ceremoniesDosage not reported*n* = 16 (14 females)Age range 21--50 (mean 33.5)EDAnorexia nervosa (10)Bulimia nervosa (6)Ayahuasca ceremonies in various settings in North, Central and South AmericaSemi-structured telephone interviews: \< 1 month (*n* = 6), 1--12 months (*n* = 6) and 1--3 years (*n* = 4) after last ayahuasca sessionTASchenberg et al. (2017) \[[@CR78]\]To test the hypothesis that ibogaine treatment combined with cognitive therapy is beneficial for patients with SUDsIbogaine HCl12 mg/kg (females)/15 mg/kg (males)Frequency not reported*n* = 22 (7 females)Age range 22--53 (mean 33)SUDsPsychotherapy in a private clinic, ibogaine administration in a hospital setting in BrazilSemi-structured face-to-face interviews, time after session not reportedDeductive content analysisSchenberg et al. (2017) \[[@CR79]\]To explore (acute) subjective experiences induced by ibogaineIbogaine HCl12 mg/kg (females)/15 mg/kg (males)Frequency not reported*n* = 22 (7 females)Age range 22--53 (mean 33)Drug dependencePsychotherapy in a private clinic, ibogaine administration in a hospital setting in BrazilSemi-structured face-to-face interviews, time after session not reportedIPABelser et al. (2017) \[[@CR82]\]To research form and content of participant experiences during psilocybin sessionsTo describe subjective experiences of the intervention in contextTo understand embedded meanings of participants' lived experiencesPsilocybin2 × 0.3 mg/kg psilocybin*n* = 13 (6 females)Age range 50 ± 15.77A projected life expectancy of at least 1 year, and a primary diagnosis of acute stress disorder, generalized anxiety disorder, anxiety disorder due to cancer, or adjustment disorder with anxietyPhase II, double-blind, crossover, placebo-controlled pilot study to assess the efficacy and safety of psilocybin in conjunction with psychotherapy on psychosocial distress with cancerSemi-structured interviews conducted 1 week (*n* = 5) or 12 months (*n* = 7) after the treatmentIPASwift et al. (2017) \[[@CR81]\]To explore psilocybin therapy experiences related to cancer and deathTo capture a more complete understanding of the treatmentPsilocybin2 × 0.3 mg/kg psilocybin*n* = 13 (6 females)Age range 50 ± 15.77Projected life expectancy of at least 1 year, and a primary diagnosis of acute stress disorder, generalized anxiety disorder, anxiety disorder due to cancer, or adjustment disorder with anxietyPhase II, double-blind, crossover, placebo-controlled pilot study to assess the efficacy and safety of psilocybin in conjunction with psychotherapy on psychosocial distress with cancerSemi-structured interviews conducted 1 week (*n* = 5) or 12 months (*n* = 7) after the treatmentIPATalin and Sanabria (2017) \[[@CR89]\]To examine people's attempts to heal substance use they see as problematicTo examine the biomedical concept of addiction in relation to ayahuasca healing practicesAyahuascaDose and frequency not reported*n* = 7Sex and age range not reportedSubstance dependence (heroin, cocaine, crack, methadone, alcohol, tobacco and antidepressants)Ayahuasca ceremonies---in Santo Daime churches in Italy. Urban ayahuasca ceremonies in BrazilParticipant observationsSemi-structured, in-depth interviewsEthnographic analysisWatts et al. (2017) \[[@CR53]\]To determine and communicate underlying psychological mechanisms in this treatment modalityPsilocybin2 × 10 and 25 mg*n* = 19 (6 females)Age range 30--64Treatment-resistant depressionOpen-label feasibility trial of psilocybin with psychological support for treatment-resistant depressionSemi-structured interviews conducted at 6 months post psilocybin doseTACamlin et al. (2018) \[[@CR86]\]To understand the subjective ibogaine experienceTo understand how ibogaine impacts individuals attempting to stop problematic opioid useIbogaineDose and frequency not reported*n* = 10 (3 females)Age range 21--48 (28.8 years)Opioid use disorderAn ibogaine treatment center in a medical facility in MexicoSemi-structured interviews conducted 3 days (*n* = 9) and 3 months post treatment (*n* = 1)Constant comparative methodNielson et al. (2018) \[[@CR77]\]To explore how patients talk about change-related phenomena during debriefing sessionsPsilocybin2 × 0.3 and 0.4 mg/kg*n* = 10Sex not reportedAge range 25--56Alcohol use disorderOpen-label pilot study of psilocybin-assisted treatment of alcohol use disorderTranscripts from 17 debriefing sessions conducted 1 day post psilocybin sessionQCANoorani et al. (2018) \[[@CR83]\]To characterize perceived mechanisms of changeTo identify themes emerging from participant accountsTo inquire about participants' experiences of the study treatmentTo understand the ways the treatment may have helped them quit smokingPsilocybin2 × 20 and 30 mg/70 kg*n* = 12 (5 females)Age range 31--67 (mean 54)Nicotine dependenceOpen-label pilot study of psilocybin-assisted treatment for smoking cessation, Baltimore (USA)Face-to-face interviews conducted, on average, 30 months after the first psilocybin sessionTARenelli et al. (2018) \[[@CR88]\]To report on the perspectives of participants who experienced both ceremonial ayahuasca drinking and conventional ED treatmentsAyahuascaDosage not reported1--30 × ceremonies*n* = 13 (12 females)Age range 21--49 (mean 30)ED:Anorexia nervosa (8)Bulimia nervosa (5)Various (1--30) ayahuasca ceremonies, rooted in Amazonian traditionsSemi-structured interviews via telephone, conducted 1 month or less (*n* = 5), 1--12 months (*n* = 5) or 12--36 months (*n* = 3) after the most recent ceremonyTAvan Schalkwyk et al. (2018) \[[@CR84]\]To explore the dissociative experience from first-person patient narrativesKetamineFrequency not reported0.5 mg/kg over 40 min intravenously*n* = 10 (7 females)Mean age 52.6Unipolar major depressive disorder (9)Bipolar disorder (1)Randomized controlled trials of ketamine vs. placebo, open-label trial of ketamine, or ketamine as clinical treatment (*n* not reported)Semi-structured interviewsMixed methodsInductive TABarone et al. (2019) \[[@CR80]\]To examine MDMA-assisted psychotherapy in a long-term follow-up contextTo complement, clarify, and expand upon quantitative findingsMDMA3 × 100--125 mg*n* = 19 (6 females)Age range 24--56Treatment-resistant PTSDPhase II RCT investigating the safety and efficacy of MDMA-assisted psychotherapy for military veterans and first responders with treatment-resistant PTSDSemi-structured interviews, conducted 12 months after the end of the trialTA and IPA*CA* content analysis, *ED* eating disorders, *HCl* hydrochloride, *IPA* interpretative phenomenological analysis, *LSD* lysergic acid diethylamide, *MDMA* 3,4-methylenedioxymethamphetamine, *PTSD* post-traumatic stress disorder, *QCA* qualitative content analysis, *RCT* randomized controlled trial, *SUDs* substance use disorders, *TA* thematic analysis

Nature of Patient Experiences {#Sec10}
-----------------------------

We primarily assessed descriptions and narratives of patient experiences. Our analysis revealed that all authors discussed one or more of the following: (1) phenomenology of the experience; (2) perspectives on the intervention; (3) therapeutic processes; and (4) outcomes of the intervention. Below we elaborate on each of the subthemes falling under these main themes, and provide key examples of each of the themes and results. In many instances, themes were reported for different substances and/or disorders. Where this was not the case, this is made explicit in the text. Quotes are included to illustrate patient experiences.

### Phenomenology of the Psychedelic Experience {#Sec11}

Several, but not all, studies explicitly addressed the phenomenology of the acute, inner experience induced by different psychedelic substances \[[@CR79], [@CR81], [@CR82], [@CR84], [@CR86]\]. In this review, we report phenomena that were not characterized as therapeutic processes alone or that did not constitute separate themes in the synthesis, while recognizing that both thematic categories are closely intertwined. Phenomenological experiences were reported on the level of altered sensory perception (including synesthesia and the perception of time), visions and visuals, and somatic effects. Respondents frequently alluded to the ineffability of the experience.

A slowed (or completely absent) perception of time and unusual bodily sensations were specifically mentioned by participants taking ketamine \[[@CR84]\], while auditory effects, such as zapping or buzzing sounds, were only mentioned for ibogaine experiences \[[@CR79], [@CR86]\]. Abstract and transient visual phenomena (such as seeing animals, complex patterns, landscapes) and visions (immersive and personally meaningful) were reported by respondents in studies with psilocybin and ibogaine \[[@CR79], [@CR81], [@CR82], [@CR86]\]. To varying degrees, these visions contained autobiographical, relational, imaginary, dreamlike, indigenous, religious, and other elements.""It sent me back to when I was very first born and felt like I was inside the womb ... I fought the devil ... he was telling me to give up and die, but I didn't want to and I somehow beat him. And that I thought was my addiction at the time ... I was able to float up in the atmosphere and I felt my grandma, I just felt her presence everywhere and I realized that she was all around the whole time." \[[@CR86]\] \[ibogaine, SUD\]."

Notably, participants who had taken ibogaine reported physically unpleasant sensations, neurological effects and perceptual alterations that were not described in other studies \[[@CR79], [@CR86]\], although unusual and strange bodily sensations were also reported for ketamine \[[@CR84]\]. Experiences of the brain being reorganized, accompanied by 'zapping' sensations, were described in studies with ibogaine \[[@CR79], [@CR86]\] and psilocybin \[[@CR91]\].""There was a little NASA space guy that came flying in and he was zapping my brain ... it felt like they were scrubbing my brain, they were just doing surgery... it felt like brain receptors being cleaned." \[[@CR86]\] \[ibogaine, SUD\]."

Somatic experiences were often connected to meaningful insights for participants with eating disorders, as evidenced by the following quote:""I saw myself as a rotting, decaying skeleton and then I saw myself as this beautiful full-bodied, just beautiful woman with this long hair, and I, like, I wanted to be that woman. I wanted to be that full, loving woman that has so much to offer my family and world. It was, and then I felt my ribs and I could feel them, they were so hollow and I was just, I was like, I can't wait to get back and just start gaining some weight." \[[@CR87]\] \[ayahuasca, eating disorder\]."

Several respondents, especially in studies with psilocybin \[[@CR77], [@CR81], [@CR82]\], and also with other substances, remarked on the ineffable nature of the experience, their inability to adequately put it into words, leading some to mention that it was easier to describe the emotional impact of the experience than the specific content.""It was a feeling beyond an intellectual feeling---it was a feeling to the bottom of my core ... that's one reason that it's hard to talk about ... it's beyond words." \[[@CR81]\] \[psilocybin, end-of-life anxiety\]."

### Perspectives on the Intervention {#Sec12}

How the treatment itself was experienced proved an important aspect for many of the respondents. This main category encompasses the following subthemes: (a) the context and structure of the treatment, and (b) comparisons with conventional treatments.

#### Context and Structure of the Intervention {#Sec13}

Independent of substance or disorder, many patients reported how they experienced the treatment, and the ways interventions were structured. Trust and a good connection or rapport with study guides, therapists and ceremonial leaders were explicitly mentioned as important therapeutic aspects \[[@CR53], [@CR80], [@CR83], [@CR87], [@CR89]\].""It's not just the psilocybin sessions \[but\] it's that human connection, and the support that comes with that human connection, that ultimately leads to success at the end of the day." \[[@CR83]\] \[psilocybin, smoking cessation\]."

Many respondents also noted the importance of the preparatory sessions \[[@CR53], [@CR80], [@CR83], [@CR90]\]; for example, in preparing them for the potential of having challenging experiences \[[@CR53]\]. The added value of integration sessions was also mentioned frequently \[[@CR53], [@CR80], [@CR82], [@CR83], [@CR87]\].""I mean besides the ayahuasca itself, besides the medicinal quality of you know, chemically what ayahuasca can do, I would say that (the most important therapeutic elements were) the trust, therapeutic trust in the medicine men and as well, the follow-up. The psychotherapy follow-up was crucial. And before and after (ceremony) I would say. I don't know if I would ever recommend an ayahuasca ceremony without that therapeutic, the first one at least, without that therapeutic follow-up." \[[@CR87]\] \[ayahuasca, eating disorder\]."

Music was used in all studies with psilocybin, MDMA, and LSD, as well as in ayahuasca ceremonies. One ibogaine study was conducted in silence \[[@CR78], [@CR79]\]; the third ibogaine study \[[@CR86]\] and the ketamine study \[[@CR84]\] did not report on this aspect. Only patients in various psilocybin studies (for end-of-life anxiety, depression, and smoking cessation) \[[@CR53], [@CR82], [@CR83]\] reflected on the role and function of music, stating that it served as a conduit, enabling them to experience and surrender to painful emotions or memories.""Music was really how everything was conveyed to me, it all came through the music ... like everything that I experienced did not really happen in the English language, it kind of happened through the music, like the music was the conduit for this experience to happen." \[[@CR82]\] \[psilocybin, end-of-life anxiety\]."

In contrast with many other classes of psychoactive substances (ketamine being a possible exception \[[@CR92], [@CR93]\]), psychedelics do not lead to addiction or dependence \[[@CR25], [@CR94]\], and some respondents with SUDs remarked on these notable differences \[[@CR79], [@CR83]\]. In two of the studies that provided a single psilocybin session, several patients expressed the wish for additional sessions \[[@CR82]\], and one study reported that several patients actively sought out extramedical psilocybin sessions for this reason \[[@CR53]\].

#### Comparisons with Other Treatments {#Sec14}

Irrespective of disorder or substance, respondents reflected on different elements of the intervention, comparing these with previously experienced conventional treatments. Many also reflected on previous strategies in coping with their disorder, and how these were addressed, often less effectively, in previous treatments \[[@CR53], [@CR78], [@CR81]\]. Below, we provide some examples of particular personalized experiences of psychedelic treatments. These are often juxtaposed generally with standard treatments, although respondents did not always specify what these treatments entailed.""Standard approaches---I guess to summarize---are very top-down ... like suppressing symptoms so that you can become functional, whereas the work with the medicine \[ayahuasca\] ... is more of a bottom up approach that is very much really rewiring things, it's getting to the root cause and bringing in what was missing and resolving it on a deep, deep level that doesn't I don't think really get fully explored or touched upon in standard approaches." \[[@CR88]\] \[ayahuasca, eating disorder\]."

Respondents from across the spectrum of disorders and substances compared their psychedelic treatments favorably to previously undergone conventional treatments, calling it, for example, more effective \[[@CR88]\], less normative \[[@CR89]\], or more rapid \[[@CR78]\], by focusing on inner processes as opposed to talk therapy \[[@CR85]\] and by providing healing beyond what they found in conventional treatments \[[@CR80]\]. Patients also favored the length of the sessions and attention they received \[[@CR53]\].""In usual psychotherapy it is mainly about talking, about words. In LSD-assisted psychotherapy it is mainly about inner processes, inner change, inner experience, it gets enriched by it." \[[@CR85]\] \[LSD, end-of-life anxiety\]."

Many respondents reflected upon the intervention's effectiveness for the specific disorder they were struggling with \[[@CR78], [@CR80], [@CR88], [@CR90]\]. In the below quote, a patient with PTSD mentions several crucial elements that together enabled him to address his (war-related) trauma.""I think that the MDMA gave me the ability to feel as though I was capable and safe of tackling the issues. Whereas before I feared those thoughts and I tried to avoid them at all times, and avoid things that reminded me of those thoughts, I think it allowed me to feel safe in my space. Of being able to fight it. I felt like I had the ability and tools, whereas before I was unarmed, unarmored, and had no support. And this type of environment, with \[the therapists\], the catalyst drug, and everything else, it felt as though I had backup. Now it was safe and I had my tools and weapons to be able to tackle the obstacles that I never had before." \[[@CR80]\] \[MDMA, PTSD\]."

Multiple patients who underwent ayahuasca ceremonies to treat eating disorders provided suggestions for integrating these with conventional eating disorder treatments \[[@CR88]\]. Respondents in one study, when prompted, actually stated becoming more open towards future conventional therapies, despite having undergone multiple therapies without success \[[@CR80]\].

### Therapeutic Processes {#Sec15}

Potential psychological or therapeutic processes or mechanisms of action constituted a major theme that, in one way or another, recurred in all studies included in this review. These cover several categories, which overlap to a certain degree. Often, there was no clear-cut distinction between the different therapeutic mechanisms, and elements of one therapeutic mechanism blended into others. Acknowledging their interrelatedness, in this review we report on the following categories: (1) insights; (2) altered self-perception; (3) feelings of connectedness; (4) transcendental experiences; and (5) expanded emotional spectrum. These are briefly discussed below.

#### Insights {#Sec16}

One of the most frequently mentioned themes was achieving insights, most crucially into one's self, alternatively called improved self-awareness or self-understanding. This was also frequently mentioned as an outcome of the intervention. For various disorders and substances, patients reported improved insights in their disorder, its root causes, and related behaviors \[[@CR80], [@CR83], [@CR87], [@CR88], [@CR90]\].""I remember having a ceremony where I really saw that at the time binging and purging and restricting were actually adaptive coping mechanisms; at the time, they were the only coping mechanisms that I actually knew to use to deal with the difficulty that I was experiencing, that I had no words for and that no one was asking about." \[[@CR87]\] \[ayahuasca, eating disorder\]."

These insights resulted in an improved understanding of the underlying disorders, the root psychological causes \[[@CR87]\], an improved understanding of the underlying causes of addiction \[[@CR90]\], and, more specifically for patients with eating disorders, somatic insights \[[@CR87]\]. Respondents also gained crucial insights into their behavior towards others with regard to relationships with friends, family or partners \[[@CR78], [@CR82]\]. Specific examples of these mechanisms were visions of an autobiographical nature \[[@CR79]\], a new understanding of death and dying \[[@CR81]\], and changes in perspective, also referred to as 'de-schematizing' \[[@CR85]\]. In one study, patients describe how insights continued to evolve across and between psilocybin sessions \[[@CR83]\].

#### Altered Self-Perception {#Sec17}

Alterations in how the self was experienced during the sessions played an important role in many studies in this review. The emphasis on changed perceptions of, and perspectives on, one's self was mentioned variably as increased self-efficacy \[[@CR78]\], decreased self-criticism \[[@CR86]\], facilitated by a lowering of psychological defense mechanisms \[[@CR53]\], and increased self-awareness \[[@CR78], [@CR80], [@CR87]\]. Closely associated were experiences of greater self-love, self-care, self-confidence, self-acceptance, self-awareness, self-worth, self-control, self-esteem, self-compassion, and self-forgiveness.""I learned a lot. I learned a lot about myself. I'd gotten to the point of questioning myself, my own morals, and for someone who hasn't done this stuff, they're not going to understand. You can see yourself like you can read a book and see everything that you stand for and kind of analyze your own self, your own thought, your own reasoning." \[[@CR80]\] \[MDMA, PTSD\]."

Related to this were experiences of a dissolving or loosening sense of self, which often gave way to a wider perspective, which was linked to transcendental experiences (see below).""Ayahuasca helped me deeply connect with myself so that self-love has been the prevalent priority over self-criticism that \[...\] self-love became more important and more prevalent. And that to me is the antidote for an eating disorder." \[[@CR87]\] ⁠ \[ayahuasca, eating disorder\]."

#### Connectedness {#Sec18}

Increased connection, or connectedness, was a central theme in one study on psilocybin treatment for depression \[[@CR53]\]. Across other studies with psilocybin, as well as with ibogaine and ayahuasca, respondents also describe (re)connection on different levels; internally (with their emotions, senses, parts of their self and their identity), as well as externally (with others, i.e. partners, family members, friends \[[@CR53], [@CR78], [@CR83], [@CR88]\], and also with nature and the world at large \[[@CR53], [@CR81], [@CR82]\].""(The psilocybin) just opens you up and it connects you ... it's not just people, it's animals, it's trees---everything is interwoven, and that's a big relief ... I think it does help you accept death because you don't feel alone, you don't feel like you're going to, I don't know, go off into nothingness. That's the number one thing---you're just not alone." \[[@CR81]\] \[psilocybin, end-of-life anxiety\]."

Experiences of interconnectedness, a felt sense of the unity of all things, were described explicitly by patients in various psilocybin studies \[[@CR53], [@CR81]--[@CR83]\].""(During the dose) I was everybody, unity, one life with 6 billion faces, I was the one asking for love and giving love, I was swimming in the sea, and the sea was me." \[[@CR53]\] ⁠ \[psilocybin, depression\]."

#### Transcendental Experiences {#Sec19}

Mystical, religious or spiritual aspects of healing were widely reported in patients' healing experiences in treatment with ayahuasca \[[@CR88], [@CR90]\], ibogaine \[[@CR79], [@CR86]\], and psilocybin \[[@CR53], [@CR81]--[@CR83]\], as well as for different mental disorders. These were related to transpersonal experiences, feelings of awe and transcendence, a dissolving of the self, a connection to greater forces, an interconnectedness with all life, and the unity of all and everything.""It was like being inside of nature, and I could've just stayed there forever---it was wonderful. All kinds of other things were coming, too, like feelings of being connected to everything, I mean, everything in nature. Everything---even like pebbles, drops of water in the sea ... it was like magic. It was wonderful, and it wasn't like talking about it, which makes it an idea, it was, like, experiential. It was like being inside a drop of water, being inside of ... a butterfly's wing. And being inside of a cheetah's eyes." \[[@CR82]\] ⁠ \[psilocybin, end-of-life anxiety\]."

#### Expanded Emotional Spectrum {#Sec20}

Across substances and disorders, respondents report on the wide emotional scope of the experience, the increased access to a range of emotions, and the importance of the emotional content of their experiences. Emotions ranging from bliss, joy, peace, and love on one end of the spectrum, to anger, anxiety, terror, dysphoria, and paranoia on the other end, were reported by respondents in the majority of the articles.""Emotionally it was a roller coaster ride ... The first time it was very brutal, painful, at least emotionally very painful. I could not even say in which direction---it just hurt, like heartache, like being disappointed, like everything you once had experienced as a negative feeling. ... It was pure pain. Pain of memories, well, or memory of pain. ... it was quite hard. During the second time it was sublime. Really. Love, expansion, holding, I knew that this sometimes happens, that participants talk about spiritual experiences. I thought they just meant this dissolution of oneself -- everything is okay, everything is great. That was a very important experience for me. Very, very important." \[[@CR85]\] \[LSD, end-of-life anxiety\]."

Sometimes a change in mood from their usual emotional state was considered therapeutic in itself.""That place was um, serene and peaceful, and um, just such a burden was lifted from me. And it was refreshing to feel something that was such a change from what I normally feel." \[[@CR84]\] \[ketamine, depression\]."

In addition to accessing previously inaccessible emotions, some respondents also describe an improved ability to process unresolved emotions \[[@CR87], [@CR88]\]. Participants regularly mentioned that experiential sessions could be challenging or painful. These emotionally difficult experiences were often considered therapeutically useful, especially when participants managed to transform negative into positive emotions, which often had a lasting impact \[[@CR53], [@CR78], [@CR81], [@CR82], [@CR85], [@CR88]\]. Closely related was the therapeutic importance of emotional catharsis, or the release of often painful emotions or memories \[[@CR53], [@CR77], [@CR79], [@CR82], [@CR85]\]. This tied in closely with participants' ability to accept, and surrender to, the difficult emotions they experienced \[[@CR53], [@CR81], [@CR82], [@CR85], [@CR88]\].""Excursions into grief, loneliness and rage, abandonment. Once I went into the anger it went 'pouf' and evaporated. I got the lesson that you need to go into the scary basement, once you get into it, there is no scary basement to go into (anymore)." \[[@CR53]\] \[psilocybin, depression\]."

In addition to accepting challenging emotional states, accepting one's situation (or more specifically, one's body and illness), particularly in the face of one's impending demise, appeared to play an important role for patients with a terminal diagnosis \[[@CR81], [@CR82], [@CR85]\].""I kind of accepted my body for what it is, and I think up until that point I resisted that ... I saw this body for what it's worth. I picked it, it's mine. It's more matter-of-fact---this is what it is. I think that acceptance has been liberating." \[[@CR81]\] \[psilocybin, end-of-life anxiety\]."

### Outcomes of the Intervention {#Sec21}

It sometimes proved difficult to distinguish outcomes of the treatment from processes participants underwent and the mechanisms described above. In many cases these overlapped: aspects that were experienced during the experiential sessions proved to have a lasting impact. Subthemes in this category include (1) symptom relief; (2) perspectives of self; (3) sense of connectedness; (4) mood and emotional changes; and (5) quality of life.

#### Symptom Relief {#Sec22}

In many studies, participants experienced significant relief from the disorder they were treated for, including reductions in eating disorder-related thoughts and symptoms, PTSD symptoms, anxiety, depression, and substance use. Reductions in withdrawal and reduced (in some cases completely vanished) craving were mentioned by participants in all studies on SUDs \[[@CR77], [@CR78], [@CR83], [@CR86], [@CR89], [@CR90]\]. Remarkably, decreased drug, alcohol, and medication use were also reported in studies with MDMA, ayahuasca and psilocybin that did not deal directly with substance use \[[@CR53], [@CR80], [@CR87]\].""When I first started \[the study\] I was taking 10 different things. And now no blood pressure medicine, no anxiety pills, no pain pills." \[[@CR80]\] \[MDMA, PTSD\]."

More broadly, outcomes were often seen beyond the realm of the initial diagnosis, and, in fact, participants often considered these other results to be more significant.""This is about a smoking study, I keep forgetting that. Because there's so much more that happened... (Smoking) just seems so petty compared to some of the stuff that was happening." \[[@CR83]\] \[psilocybin, smoking cessation\]."

#### Perspectives of Self {#Sec23}

Therapeutic outcomes were often discussed in the realm of the self. Previously mentioned shifts in self-perception as therapeutic process often remained with patients, who described being better able to understand, reflect on, or be aware of themselves \[[@CR53], [@CR80], [@CR83], [@CR87]\], experienced greater self-confidence and self-esteem \[[@CR87]\], as well as self-acceptance \[[@CR86]\], and found themselves better able to feel love and compassion for themselves \[[@CR80], [@CR87], [@CR88]\], leading to better self-care \[[@CR88]\].""\[Ibogaine\] gave me more self-love ... I'm not so hard on myself." \[[@CR86]\] \[ibogaine, SUD\]."

#### Sense of Connectedness {#Sec24}

Enhanced (inter)connectedness was reported across substances, both during sessions and afterwards, with respondents alluding to positive changes in friendships and improved relationships with family members \[[@CR53], [@CR78], [@CR80]\]. One article describes increased altruism and prosocial activities in general \[[@CR83]\].""\[I feel\] love, compassion, and it's not just for family, it's for everyone...\[my parents and I\] have a much better relationship now, no doubt... the study helped me really get there." \[[@CR80]\] \[MDMA, PTSD\]."""I think right after the trips ... certain changes happened ... Same things were not equally important anymore. A shift in values. ... To take time to listen to music, to listen to music consciously. Maybe that material values were not that important anymore. That other values have priority. Health and family, such things... When you have a job and the job has priority and the family comes last. You don't even notice it anymore. To realize there, stop, what is actually important? That the family is fine, that the kids are doing well ..." \[[@CR85]\] \[LSD, end-of-life anxiety\]."

#### Emotions {#Sec25}

Participants also reported improved mood, greater optimism, an increased emotional repertoire, and positive emotional changes \[[@CR53], [@CR78], [@CR82], [@CR84]\]. In some cases, this included increased confidence in dealing with future adverse situations, such as a relapse in symptoms or the recurrence of their illness \[[@CR53], [@CR81]\].""Though my problems obviously have not stopped to happen and appear, I changed in the face of them. So, I get to the end of my day very grateful, very happy." \[[@CR78]\] \[ibogaine, SUD\]."

#### Quality of Life {#Sec26}

Across the board, respondents in these studies describe positive and often lasting changes in quality of life and well-being \[[@CR78], [@CR82], [@CR85]\], experiencing an increased sense of peace and mental space in daily life \[[@CR53], [@CR81], [@CR84]\]. Respondents also mentioned an increased sense of purpose or meaning in life \[[@CR81]\]. Increased appreciation of beauty in art, music, and nature was reported by several participants \[[@CR53], [@CR83]\].""A veil dropped from my eyes, things were suddenly clear, glowing, bright. I looked at plants and felt their beauty. I can still look at my orchids and experience that: that is the one thing that has really lasted." \[[@CR53]\] \[psilocybin, depression\]."

In one study, participants report being able to maintain this sense of well-being even after relapsing or after symptoms return \[[@CR53]\]. These positive changes in quality of life were reflected in the positive changes participants made, such as re-engaging with previously enjoyed activities such as practicing sports, changing nutritional habits, reading poetry and other hobbies. Changes in quality of life seemed associated with revised priorities in life or more clarity around values, as exemplified by one participant.""I had lost desire to do anything, I lacked will to go to the gym, to the park, the cinema, I only wanted to stay home. After ibogaine the first thing I wanted to do was going to the park, to the movies" \[[@CR78]\] \[ibogaine, SUD\]."

Discussion {#Sec27}
==========

This paper is the first to systematically offer an overview and thematic synthesis of the qualitative empirical literature that describes patient experiences of treatments using a psychedelic substance for the treatment of a mental disorder. All included qualitative studies were published in the last 5 years, which is indicative of both the increasing interest in therapeutic applications of psychedelics and a growing appreciation of qualitative methods in clinical research; half of the studies complemented quantitative measurements in clinical trials. We used a broad definition of psychedelics that included a range of pharmacologically diverse substances: the 'classical' serotonergic psychedelics psilocybin, LSD, and ayahuasca; MDMA; ibogaine; and ketamine, which were used to treat several distinct mental disorders. This was driven by the presumed shared phenomenology of psychedelics \[[@CR26]\], combined with the strong phenotypic overlap or high comorbidity between psychiatric diagnostic categories \[[@CR95]\], the genetic overlap between mental disorders \[[@CR96]\], as well as the absence of reliable biomarkers \[[@CR97]\] or natural boundaries \[[@CR98], [@CR99]\] to distinguish disorders, and also the fact that diagnostic categories can change over time \[[@CR99]--[@CR101]\]. Furthermore, there is evidence to support the idea that the subjective experience induced by these compounds is relevant for their therapeutic effect. To some degree, this also holds true for ketamine, which is nevertheless predominantly administered as a standalone pharmacotherapy \[[@CR2], [@CR27], [@CR102]--[@CR104]\]. In some instances, a single substance (e.g. psilocybin) was used for the treatment of varying mental disorders: depression, nicotine dependence, alcohol use disorder and end-of-life distress. Similarly, different substances (psilocybin, LSD, ayahuasca and ketamine) were studied for the treatment of the same disorder (e.g. depression).

Despite the oft-reported ineffability (the inability to adequately verbalize the phenomenological content of their experiences), respondents in several studies did offer rather detailed descriptions of their experiences, as well as reflections on the intervention. Not all studies described phenomenological aspects of the acute experience; this is most likely related to the specific methodology used or the researchers' areas of interest.

For a critical appraisal of the qualitative assessment of the participants' experience, it is important to understand when, by whom, and how data collection and analysis were performed. Given the timing of interviews, which varied considerably (from 1 week to 1 year post-session; for an overview see Table [3](#Tab3){ref-type="table"}), also within studies, respondents may not always have had enough time or distance to gain a broader perspective on their experiences, or to experience longer-term changes in the first place. As some respondents alluded to, insights were not always gained during the interventions themselves, but rather between sessions, or following (integrative) sessions \[[@CR83]\].

Interestingly, in some studies, treatment-resistant patients in placebo groups reported enduring, clinically significant improvements (see, for example \[[@CR8]\]). This may illustrate the importance attributed to extrapharmacological factors that were mentioned by respondents: trust, interpersonal rapport, attention, the length of treatment sessions, and a safe treatment setting. However, since several studies were uncontrolled or open-label, contextual factors could not be discriminated from drug effects. Music was also frequently mentioned as an important element. This is in line with the role of music in both traditional ceremonial psychedelic use and present-day clinical psychedelic research \[[@CR105]\], suggesting that therapeutic benefits may be promoted not only by the drug but by its interaction with music \[[@CR106]\]. Music is typically used to elicit personally meaningful experiences by intensifying emotions and mental imagery; guiding or supporting emerging experiences; and by providing non-verbal structure, grounding, and continuity \[[@CR33], [@CR105], [@CR106]\].

Therapeutic alliance is considered a strong predictor of treatment success in conventional psychotherapy \[[@CR107]\]. The value respondents attributed to surrendering to and overcoming intense, emotionally challenging experiences suggests that therapeutic alliance may be crucial in establishing patient safety. Participants also stressed the importance of preparatory and integration sessions in this respect.

This review revealed several therapeutic mechanisms, all reported for multiple substances and disorders. Mechanisms include gaining insights, altered self-perception, increased feelings of connectedness, transcendental experiences, and expanded emotional spectrum. These mechanisms often overlapped; elements of one therapeutic mechanism also featured in descriptions of others. For example, insights into relationships with family or friends related to experiences of connectedness, while experiences of interconnectedness can also be labeled as mystical. Likewise, an emotional breakthrough can follow insight into the origins of one's depression and may be prompted by having surrendered to a particularly challenging experience. It is plausible that multiple mechanisms, or elements thereof, may act together in producing therapeutically relevant outcomes.

Descriptions of therapeutic processes were closely intertwined with the phenomenology of the subjective experience, and were often difficult to distinguish from treatment outcomes. This can be explained by the presumed therapeutic effect of the subjective experience itself, making it difficult to disentangle the two. It is also partially inherent to the interpretative process of analyzing and synthesizing qualitative data. Patient reports can be ambivalent and it is not always clear whether they refer to acute experiences or longer-term outcomes. Patients reported a range of insights, changed perspectives and increased understanding, into the self and (root causes of) their disorder. Insights and altered self-perception were related to outcomes such as increased self-love, self-worth, and self-compassion. Again, these were described irrespective of a specific disorder or substance. Some participants reported experiences of ego dissolution, often linked to feelings of connection to larger existential powers. These spiritual or mystical aspects of healing were also mentioned across substance and disorder. Both early \[[@CR108]--[@CR110]\] and present-day psychedelic studies \[[@CR13], [@CR14], [@CR51], [@CR111], [@CR112]\] have found significant relations between mystical experiences and therapeutic outcomes. Experiences of interconnectedness emerged as a theme in all psilocybin studies; 'connectedness' constituted a major theme in one study \[[@CR53]\], prompting new hypotheses and the development of new scales \[[@CR52]\]. Psychedelics may intensify emotions and have been used for this purpose since early psychotherapy research in the 1950s \[[@CR113]\]. Patients also considered improved access to a greater range of emotions and emotional content important, particularly being able to process and release previously unresolved or inaccessible emotions. The fact that catharsis or emotional breakthrough may act as a mediating determinant in long-term positive changes in well-being is partially validated by recent online surveys \[[@CR55]\]. Furthermore, patients explicitly attributed value to overcoming difficult experiences. These are thought to be a mediating factor in both negative and positive long-term effects of treatment with psychedelics \[[@CR114]--[@CR116]\]. Evidence from survey studies indicated that the peak intensity of challenging experiences was associated with positive long-term outcomes, provided resolution was achieved, as longer duration was predictive of negative outcomes \[[@CR116]\].

Respondents reported both clinically and personally meaningful outcomes. An interesting finding was that many patients reported benefits beyond symptom reduction. In fact, they did not always consider symptom reduction to be the primary benefit. In all studies on SUDs, respondents reported decreases in craving and withdrawal symptoms \[[@CR77]--[@CR79], [@CR83], [@CR86], [@CR89], [@CR90]\]. Interestingly, these reductions were also reported by patients with depression, eating disorders, and PTSD. While there has been substantial anecdotal, albeit not clinical, evidence to suggest that ibogaine in particular is capable of attenuating (opioid) withdrawal \[[@CR43], [@CR117]\], reduction and elimination of craving and withdrawal symptoms were also reported in studies with ayahuasca \[[@CR90]\], psilocybin \[[@CR83]\] and MDMA \[[@CR80]\]. Since many mental disorders have high comorbidity with SUDs \[[@CR118]--[@CR121]\], this may explain why the therapeutic action of psychedelics may need not be limited to a specific disorder or (set of) symptoms.

This review had several limitations. First, studies included in this review varied in terms of design, qualitative research methodology, analysis methods, timing of the interviews, and overall quality. These factors may have influenced results and reduced comparability. Second, we considered mental disorders non-specifically. Compounded by the diversity of substances and heterogeneity of treatment contexts, it could be argued that this review compared orchard-grown apples with indoor-cultivated oranges. Given the overlap in phenomenology of these diverse substances, the various mental disorders, and combined with the novelty of this field, and the relative paucity of the available evidence, this review was meant to serve an exploratory purpose and was not intended to yield comparative results (as, indeed, this would require more studies per substance and per disorder, as well as a multidimensional matrix). As a result, substance-specific characteristics for the treatment of specific disorders could not be teased out. It has been suggested that MDMA, for example, possesses characteristics that make it uniquely useful for the treatment of PTSD \[[@CR122]\]; the same has been argued for ibogaine in the treatment of SUD \[[@CR42]\]. The high heterogeneity of the articles included in this review do not provide sufficient evidence to establish these relations. While this review does not suggest that all substances have the same effect, its results do indicate that psychedelics---perhaps with the exception of ketamine (as there were insufficient qualitative data)--may induce states of consciousness that are considered valuable by patients, suggesting a broad applicability of different psychedelics for mental disorders. More research is needed to substantiate this claim, or to establish whether some substances are indeed more qualified for the treatment of specific disorders. Third, it is possible that respondents' favorable reports of their psychedelic treatments, when contrasted with previous (unsuccessful) conventional treatments, may be attributed to selection or expectation bias. Indeed, a substantial proportion of participants reported prior experience with psychedelics; this ranged from 10% with LSD \[[@CR12]\] to 23% with ecstasy (MDMA) \[[@CR7]\], and 25% \[[@CR20]\], 55% \[[@CR13]\] and 67% \[[@CR4]\] reported prior experience with psilocybin. None of the studies on ibogaine and ketamine reported on this; all studies on ayahuasca, where reported, included participants who had undergone between one and 30 ceremonies. Additionally, in various studies, patients were self-selected, meaning they may not be representative for the larger population in seeking out these novel treatment modalities. Lastly, it is possible that research in this field, as in any new (or reappearing) research topic, overvalues positive aspects of these treatments \[[@CR123]\]. Patient selection in pioneer studies is often (unintentionally) biased towards positive outcomes, and study samples are still small and non-generalizable. More studies in larger and more heterogeneous patient samples would be needed to appraise the real impact and ecological validity of these treatments.

The advent of psychedelic treatments has recently been labeled a new paradigm for psychiatry \[[@CR124]\]. Patients frequently report on clinical effects beyond their psychiatric diagnosis, and pharmacologically distinct substances appear to exert comparable therapeutic processes for the same mental disorders. Psychedelic treatments may well contribute to a new sort of non-specific 'precision medicines' \[[@CR125]\] or 'targeted psychotherapies' of mental disorders, by setting in motion subjective therapeutic processes that address root causes or core elements of a single psychopathology dimension (also called p-factor \[[@CR126]\]) that manifest differently as different mental disorders. Since it is not well understood how psychotherapies contribute to change \[[@CR127]\], it remains important to study these complexities more closely.

Conclusions {#Sec28}
===========

Treatments for mental disorders involving psychedelics are receiving renewed attention and scrutiny. The therapeutic mediators and mechanisms through which these compounds contribute to treatment outcomes remain insufficiently understood. Our review revealed several connected therapeutic processes---seen across substances and for different disorders---that contributed to clinically significant and personally meaningful outcomes. Exploring patient experiences can increase our understanding of underlying therapeutic mechanisms and processes, the role of (extra)pharmacological factors in these treatment modalities, which may contribute to optimizing treatment context, and lead to improved clinical responses and personal benefits. Despite the heterogeneity of substance, setting, and population, these studies also suggest that, in addition to a shared phenomenology, psychedelic treatments exhibit similar therapeutic processes and result in comparable outcomes. As this review demonstrates, qualitative research of psychedelic treatments can contribute to distinguishing specific features of these compounds, and show potential for elucidating otherwise undiscovered implications for the treatment of distinct mental disorders.

Appendix 1 {#Sec29}
==========

An overview of the included studies and scores according to the Critical Appraisal Skills Programme (CASP) checklist: low, medium, highAuthor(s)**1. Aims**\
Was there a clear statement of the aims of the research?**2. Appropriateness**\
Is a qualitative methodology appropriate?**3. Research design**\
Was the research design appropriate to address the aims of the research?**4. Sampling**\
Was the recruitment strategy appropriate to the aims of the research?**5. Data collection**\
Were the data collected in a way that addressed the research issue?**6. Researcher role**\
Has the relationship between researcher and participants been adequately considered?**7. Ethics**\
Have ethical issues been taken into consideration?**8. Data analysis**\
Was the data analysis sufficiently rigorous?**9. Findings**\
Is there a clear statement of findings?**10. Value**\
How valuable is the\
research?**Overall assessment**Loizaga-Velder and Verres (2014) \[[@CR90]\]HighHighHighHighMediumLowLowMediumHighHighMedium/highGasser et al. (2015) \[[@CR85]\]MediumHighHighHighHighLowLowMediumMediumHighMedium/highLafrance et al. (2017) \[[@CR87]\]HighHighHighHighHighMediumHighHighHighHighHighSchenberg et al. (2017) \[[@CR78]\]LowLowLowMediumMediumLowHighMediumMediumMediumLowSchenberg et al. (2017) \[[@CR79]\]HighHighHighMediumHighHighHighMediumMediumHighMedium/highBelser et al. (2017) \[[@CR82]\]HighHighHighHighHighMediumHighHighHighHighHighSwift et al. (2017) \[[@CR81]\]HighHighHighHighHighLowHighMediumHighHighHighTalin and Sanabria (2017) \[[@CR89]\]MediumHighHighLowMediumMediumLowLowLowMediumMediumWatts et al. (2017) \[[@CR53]\]MediumHighHighHighHighHighHighMediumHighHighHighCamlin et al. (2018) \[[@CR86]\]MediumHighMediumLowHighMediumHighMediumMediumHighMediumNielson et al. (2018) \[[@CR77]\]HighHighHighHighHighHighHighHighHighHighHighNoorani et al. (2018) \[[@CR83]\]HighHighHighHighHighHighHighHighHighHighHighRenelli et al. (2018) \[[@CR88]\]HighHighHighHighHighMediumMediumMediumHighHighHighvan Schalkwyk et al. (2018) \[[@CR84]\]HighHighHighHighHighHighMediumHighHighHighHighBarone et al. (2019) \[[@CR80]\]MediumMediumMediumHighHighHighHighMediumHighHighMedium/high
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